Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | 0.00 |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 13.48M | 4.21M | 3.54M | 2.21M | 2.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.18M | 10.19M | 8.61M | 5.79M | 5.55M |
| Operating Income | -17.18M | -10.19M | -8.61M | -5.79M | -5.55M |
| Income Before Tax | -16.15M | -9.35M | -7.36M | -5.06M | -4.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.15M | -9.35M | -7.36M | -5.06M | -4.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.15M | -9.35M | -7.36M | -5.06M | -4.72M |
| EBIT | -17.18M | -10.19M | -8.61M | -5.79M | -5.55M |
| EBITDA | -17.16M | -10.18M | -8.60M | -5.77M | -5.52M |
| EPS Basic | -0.39 | -0.24 | -0.33 | -0.48 | -0.18 |
| Normalized Basic EPS | -0.25 | -0.15 | -0.21 | -0.30 | -0.11 |
| EPS Diluted | -0.39 | -0.24 | -0.33 | -0.48 | -0.18 |
| Normalized Diluted EPS | -0.25 | -0.15 | -0.21 | -0.30 | -0.11 |
| Average Basic Shares Outstanding | 41.16M | 38.60M | 22.08M | 10.64M | 25.83M |
| Average Diluted Shares Outstanding | 41.16M | 38.60M | 22.08M | 10.64M | 25.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |